Europe Malaria Treatment Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Treatment Type (Antimalarial Agents, and Diagnostic Test); Route of Administration (Oral, and Parenteral); End User (Hospitals, Specialty Clinics, and Others)
The Europe malaria treatment market is expected to grow from US$ 593.03 million in 2022 to US$ 785.75 million by 2028. It is estimated to register a CAGR of 4.8% from 2022 to 2028.
Extending Pipeline of New Drugs and Vaccines is Driving the Europe Malaria Treatment Market
Antimicrobial resistance threatens the public health response to many diseases, such as malaria, and the R&D of new medicines is the best strategy to overcome this challenge.With this, the antimalarial drug/vaccine pipeline is becoming increasingly robust.
Public–private partnerships are accelerating research activities in the malaria treatment market, creating lucrative opportunities for the market growth.For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, is working with many pharmaceutical companies to reduce the burden of malaria by developing novel treatment options.
In December 2019, Ipca Laboratories collaborated with MMV to develop Atoguanil, a novel antimalarial coformulation. So, extending pipeline of new drugs and vaccines is expected to drive the Europe malaria treatment market .
Europe Malaria Treatment Market Overview
The Europe malaria treatment market includes the UK, Germany, France, Italy, Spain, and the Rest of Europe.Germany dominated the market in 2022.
According to the European Center for Disease Prevention and Control report, in 2019, 8,641 malaria cases were registered in the European Union (EU), among which 8,638 (>99%) were malaria-confirmed cases. Additionally, 5,509 cases (99.8%) of malaria cases were travel-related, among which two were registered in Germany. The cases in Germany were infected by vector-borne transmission. The EU supports eradicating malaria by aiming to facilitate the development and producing a highly efficacious malaria vaccine. For example, in July 2021, backed by the eradicate Malaria initiative, German company BioNTech announced a malaria project focusing on developing an mRNA-based vaccine against the disease and evaluating mRNA vaccine production in Africa. Moreover, in September 2022, Germany signed an agreement worth US$ 1.34 billion with The Joint United Nations Programme on HIV/AIDS (UNAIDS), aiming to fight AIDS, tuberculosis, and malaria with an increase of 30% of the country’s contribution from 2019. Further, from 2010 to 2020, international sources provided 69% of total funding aiming for malaria control and elimination, as per the endmalaria.org 2020 report. For example, total funding for malaria control and elimination accounted for US$ 3.3 billion; Germany contributed US$ 0.2 billion.
Europe Malaria Treatment Market Revenue and Forecast to 2028 (US$ Million)
Europe Malaria Treatment Market Segmentation
The Europe malaria treatment market is segmented based on treatment, drug type, route of administration, distribution channel, end user, and country.
Based on treatment, the Europe malaria treatment market is segmented into prescription medications, vaccines, diagnostic tests, and others.The diagnostic tests segment held the largest market share in 2022.
The prescription medications segment is further categorized into chloroquine phosphate, artemisinin-based combination therapies (ACTs), atovaquone-proguanil, quinine sulfate (qualaquin) with doxycycline, primaquine phosphate, and others.
Based on drug type, the Europe malaria treatment market is bifurcated into branded and generic. The generic segment held a larger market share in 2022.
Based on route of administration, the Europe malaria treatment market is bifurcated into oral and parenteral & intravenous. The oral segment held a larger market share in 2022.
Based on distribution channel, the Europe malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022.
Based on end user, the Europe malaria treatment market is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment held the largest market share in 2022.
Based on country, the Europe malaria treatment market has been categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany dominated the market in 2022.
AdvaCare Pharma USA LLC, Cipla Ltd, GSK Plc, Lupin Ltd, Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd, Viatris Inc, and Zydus Healthcare Ltd are among the leading companies operating in the Europe malaria treatment market.